Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies

Research output: Contribution to journalReview articlepeer-review

68 Scopus citations

Abstract

Deficiencies in the brain's own adenosine-based seizure control system contribute to seizure generation. Consequently, reconstitution of adenosinergic neuromodulation constitutes a rational approach for seizure control. This review will critically discuss focal adenosine augmentation strategies and their potential for antiepileptic and disease modifying therapy. Due to systemic side effects of adenosine focal adenosine augmentation - ideally targeted to an epileptic focus - becomes a therapeutic necessity. This has experimentally been achieved in kindled seizure models as well as in post-status epilepticus models of spontaneous recurrent seizures using three different therapeutic strategies that will be discussed here: (i) polymer-based brain implants that were loaded with adenosine; (ii) brain implants comprised of cells engineered to release adenosine and embedded in a cell-encapsulation device; (iii) direct transplantation of stem cells engineered to release adenosine. To meet the therapeutic goal of focal adenosine augmentation, genetic disruption of the adenosine metabolizing enzyme adenosine kinase (ADK) in rodent and human cells was used as a molecular strategy to induce adenosine release from cellular brain implants, which demonstrated antiepileptic and neuroprotective properties. New developments and therapeutic challenges in using AATs for epilepsy therapy will critically be evaluated.

Original languageEnglish (US)
Pages (from-to)131-141
Number of pages11
JournalEpilepsy Research
Volume85
Issue number2-3
DOIs
StatePublished - Aug 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Keywords

  • Adenosine
  • Cell therapy
  • Epilepsy
  • Gene therapy
  • Kindling
  • Silk

Fingerprint

Dive into the research topics of 'Adenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies'. Together they form a unique fingerprint.

Cite this